Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Open access
Solomon, Benjamin J., Tan, Lavinia, Lin, Jessica J., Wong, Stephen Q., Hollizeck, Sebastian, Ebata, Kevin, Tuch, Brian B., Yoda, Satoshi, Gainor, Justin F., Sequist, Lecia V., Oxnard, Geoffrey R., Gautschi, Oliver, Drilon, Alexander, Subbiah, Vivek, Khoo, Christine, Zhu, Edward Y., Nguyen, Michele, Henry, Dahlia, Condroski, Kevin R., Kolakowski, Gabrielle R., Gomez, Eliana, Ballard, Joshua, Metcalf, Andrew T., Blake, James F., Dawson, Sarah-Jane, Blosser, Wayne, Stancato, Louis F., Brandhuber, Barbara J., Andrews, Steve, Robinson, Bruce G., Rothenberg, S. Michael·2020·Journal of Thoracic Oncology

Abstract

INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC). However, the mechanisms of resistance to these agents have not yet been described. METHODS: Analysis was performed of circulating tumor DNA and tissue in patients with RET fusion-positive NSCLC and RET-mutation positive MTC who developed disease progression after an initial response to selpercatinib. Acquired resistance was modeled preclinically using a CCDC6-RET fusion-positive NSCLC patient-derived xenograft. The inhibitory activity of anti-RET multikinase inhibitors and selective RET TKIs was evaluated in enzyme and cell-based assays. RESULTS: After a dramatic initial response to selpercatinib in a patient with KIF5B-RET NSCLC, analysis of circulating tumor DNA revealed emergence of RET G810R, G810S, and G810C mutations in the RET solvent front before the emergence of clinical resistance. Postmortem biopsy studies reported intratumor and intertumor heterogeneity with distinct disease subclones containing G810S, G810R, and G810C mutations in multiple disease sites indicative of convergent evolution on the G810 residue resulting in a common mechanism of resistance. Acquired mutations in RET G810 were identified in tumor tissue from a second patient with CCDC6-RET fusion-positive NSCLC and in plasma from patients with additional RET fusion-positive NSCLC and RET-mutant MTC progressing on an ongoing phase 1 and 2 trial of selpercatinib. Preclinical studies reported the presence of RET G810R mutations in a CCDC6-RET patient-derived xenograft (from a patient with NSCLC) model of acquired resistance to selpercatinib. Structural modeling predicted that these mutations sterically hinder the binding of selpercatinib, and in vitro assays confirmed loss of activity for both anti-RET multikinase inhibitors and selective RET TKIs. CONCLUSIONS: RET G810 solvent front mutations represent the first described recurrent mechanism of resistance to selective RET inhibition with selpercatinib. Development of potent inhibitor of these mutations and maintaining activity against RET gatekeeper mutations could be an effective strategy to target resistance to selective RET inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.01.006

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 289

Metadata

Authors
Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., Oxnard, G. R., Gautschi, O., Drilon, A., Subbiah, V., Khoo, C., Zhu, E. Y., Nguyen, M., Henry, D., Condroski, K. R., Kolakowski, G. R., Gomez, E., Ballard, J., Metcalf, A. T., Blake, J. F., Dawson, S.-J., Blosser, W., Stancato, L. F., Brandhuber, B. J., Andrews, S., Robinson, B. G., & Rothenberg, S. M.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-04
Volume
15
Issue
4
Pages
541-549
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3000979489
Cited by
289
References
22
FWCI
22.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. https://app.cochat.ai/papers/10.1016/j.jtho.2020.01.006
The paper
Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., Oxnard, G. R., Gautschi, O., Drilon, A., Subbiah, V., Khoo, C., Zhu, E. Y., Nguyen, M., Henry, D., Condroski, K. R., . . . Rothenberg, S. M. (2020). RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.01.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.